Clinical trials: Left Side
EF Evaluation From 4 Chamber Plane, EF Evaluation From 2 Chamber Plane
Automated Left Ventricular Function Evaluation by LVivoEF
Left ventricular ejection fraction (EF) is evaluated in every echocardiographic examination either by visual estimation (eyeballing) requiring high level of training and expertise and/or by manual tracing of the endocard from…
- Conditions
- EF Evaluation From 4 Chamber Plane, EF Evaluation From 2 Chamber Plane, Biplane EF Evaluation, Left Ventricular Function
- Trial name
- LVivoEF (NCT01515267)
- Where
- Israel
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- DiA Imaging Analysis Ltd
Acute Myocardial Infarction (AMI)
Counterpulsation Reduces Infarct Size Pre-PCI for AMI
Subjects with anterior acute STEMI who receive an IABC before primary PCI will have decreased MI size.
- Trial name
- CRISP-AMI (NCT00833612)
- Testing
- Counterpulsation with IAB
- Where
- 40 sites in United States, Australia and 8 more
- Volunteers
- 339 people
- Sponsor
- Datascope Corp.
Heart Failure
EASYTRAK 3 Downsize Lead
The primary objective of this clinical investigation is to evaluate the safety and effectiveness of the EASYTRAK 3 Downsize Lead.
- Trial name
- NCT00384722
- Testing
- EASYTRAK 3 Downsize Lead
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- Boston Scientific Corporation
Pulmonary Disease, Chronic Obstructive
Cardiovascular Function in COPD Patients
The objectives of the study are to explore the effect of treatment with tiotropium + olodaterol fixed dose combination (FDC) compared to fluticasone propionate + salmeterol FDC on: reversal of left ventricular diastolic…
- Trial name
- NCT03055988
- Testing
- Tiotropium, Olodaterol, Fluticasone propionate
- Where
- 10 sites in Germany
- Volunteers
- 76 people
- Sponsor
- Boehringer Ingelheim
Atrial Fibrillation
Continued Access to PREVAIL (CAP2) - WATCHMAN Left Atrial Appendage (LAA) Closure Technology
To provide additional information about the safety and efficacy of the WATCHMAN LAA Closure Technology
- Trial name
- CAP2 (NCT01760291)
- Testing
- WATCHMAN LAA Closure Technology
- Where
- 3 sites in United States
- Volunteers
- 576 people
- Sponsor
- Boston Scientific Corporation
Chronic Heart Failure, Left Ventricular (LV) Systolic Dysfunction
A Study Evaluating an Implantable Cardiac Microcurrent Device in Patients With Chronic Heart Failure
This study evaluates the safety and performance/effectiveness of the C-MIC System, an active implantable medical device designed to treat patients with heart failure with reduced ejection fraction (HFrEF).
- Conditions
- Chronic Heart Failure, Left Ventricular (LV) Systolic Dysfunction, Ischemic and Non-ischemic Cardiomyopathy
- Trial name
- NCT07795359
- Testing
- Subcutaneous cardiac microcurrent treatment
- Volunteers
- 60 people
- Sponsor
- Berlin Heals GmbH
Heart Failure, Left Ventricle Remodeling
ALIVE Expended Access - Clinical Study
A prospective, multi-center, single-arm study. This study will enroll a maximum of 35 subjects treated with the Revivent TC System.
- Trial name
- ALIVE-EA (NCT05710042)
- Testing
- Revivent TC System
- Where
- 2 sites in United States
- Sponsor
- BioVentrix
Atrial Fibrillation
Effects of Dronedarone on Cardiac Geometry and Function in Patients With Atrial Fibrillation and Left Atrial Enlargement
Primary Objective: Evaluate the effect of dronedarone versus placebo (standard therapy) in slowing the progression of adverse left atrial remodeling in patients with atrial fibrillation (AF) following 12 months of treatment.
- Trial name
- ODYSSEUS (NCT01198873)
- Testing
- Dronedarone
- Where
- 57 sites in United States, Canada
- Volunteers
- 76 people
- Sponsor
- Sanofi
Congestive Heart Failure, Left Ventricular Systolic Dysfunction
Sleep-Disordered Breathing in Heart Failure - The SchlaHF-Registry
Objective target of the registry is to investigate the prevalence of SDB as well as the clinical characteristics of patients with and without SDB as well as the predominant type of sdb.
- Trial name
- SchlaHF (NCT01500759)
- Where
- 199 sites in Australia, Germany
- Volunteers
- 6,876 people
- Sponsor
- ResMed
Congestive Heart Failure
Post Approval Registry of Corox OTW, Endocardial, Left Ventricular Steroid Lead, Bipolar
The objective of this study is to confirm the long-term safety and reliability of the Corox OTW BP left ventricular (LV) pacing lead.
- Trial name
- CELESTIAL (NCT00810264)
- Testing
- CRT Therapy - LV Lead Registry
- Where
- 86 sites in United States
- Volunteers
- 2,499 people
- Sponsor
- Biotronik, Inc.
Coagulation
Left Ventricular Assist Device (LVAD) Specialized Centers of Clinically Orientated Research (SCCOR) Coagulation - Acute Intrinsic Pathway Antagonist (IPA)
The purpose of this study is to determine if post-operative administration of intrinsic pathway antagonist (TTP889) in patients on Left Ventricular Assist Device (LVAD) support will result in a 50% reduction of thrombin…
- Trial name
- NCT00909298
- Testing
- TTP889
- Where
- 3 sites in United States
- Volunteers
- 2 people
- Sponsor
- vTv Therapeutics
Acute Myocardial Infarction, Congestive Heart Failure
IK-5001 for the Prevention of Remodeling of the Ventricle and Congestive Heart Failure After Acute Myocardial Infarction
The primary objective is to evaluate the safety and effectiveness of the IK-5001 device for the prevention of ventricular remodeling and congestive heart failure when administered to subjects who had successful percutaneous…
- Conditions
- Acute Myocardial Infarction, Congestive Heart Failure, ST-Elevation Myocardial Infarction
- Trial name
- PRESERVATION-1 (NCT01226563)
- Testing
- IK-5001, Saline Solution
- Where
- 82 sites in United States, Australia and 7 more
- Volunteers
- 303 people
- Sponsor
- Bellerophon BCM LLC
Healthy Participants
A Study to Evaluate the Effects of Mavacamten in Healthy Participants
The purpose of the study is to evaluate the effect between two different single doses of mavamten in healthy participants.
- Trial name
- NCT05719805
- Testing
- Mavacamten
- Where
- 2 sites in United States
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Acute Myocardial Infarction
Prospective ARNI vs ACE Inhibitor Trial to DetermIne Superiority in Reducing Heart Failure Events After MI
The purpose of this study is to evaluate the efficacy and safety of LCZ696 titrated to a target dose of 200 mg twice daily, compared to ramipril titrated to a target dose of 5 mg twice daily.
- Trial name
- PARADISE-MI (NCT02924727)
- Testing
- LCZ696 (sacubitril/valsartan), Ramipril, Valsartan
- Where
- 486 sites in United States, Argentina and 39 more
- Volunteers
- 5,669 people
- Sponsor
- Novartis Pharmaceuticals
Percutaneous Coronary Intervention, Coronary Artery Disease
Clinical Evaluation of A New High-speed and High-resolution Intravascular Ultrasound System
Insight Lifetech Intravascular Ultrasound Diagnostic System (referred to as Insight Lifetech IVUS system below),is a new high-speed and high-resolution device for clearly defining vessel architecture and plaque morphology…
- Conditions
- Percutaneous Coronary Intervention, Coronary Artery Disease, Chronic Total Occlusion of Coronary Artery, Left Main Coronary Artery Disease
- Trial name
- NEW-IVUS (NCT04739657)
- Testing
- Insight Lifetech IVUS System, Boston Scientific IVUS System
- Where
- 5 sites in China
- Volunteers
- 130 people
- Sponsor
- Insight Lifetech Co., Ltd.
Heart Failure
Evaluation of the Safety and Effectiveness of the DuraHeart™ LVAS
Specific Aims The aims of this trial are to evaluate the safety and effectiveness of the DuraHeart™ LVAS in patients with advanced heart failure who require LVAS support as a bridge to cardiac transplantation.
- Trial name
- NCT00710567
- Testing
- DuraHeart Left Ventricular Assist System (LVAS)
- Where
- 26 sites in United States, Canada
- Volunteers
- 66 people
- Sponsor
- Terumo Heart Inc.
Atrial Fibrillation, AFib
Stroke Feasibility Study
This is a feasibility study to assess the safety and efficacy of the AtriCure AtriClip when placed via Minimally Invasive Surgical Deployment to the Left Atrial Appendage.
- Trial name
- NCT01997905
- Testing
- AtriClip LAA Exclusion Device
- Where
- 7 sites in United States
- Volunteers
- 13 people
- Sponsor
- AtriCure, Inc.
Coronary Heart Disease
Levosimendan Pretreatment for Weaning Patients From Cardio-Pulmonary Bypass
The study evaluates the efficacy of intravenous levosimendan treatment started during a coronary artery bypass operation to wean patients from a heart lung machine.
- Trial name
- NCT00130871
- Testing
- levosimendan
- Where
- 2 sites in Finland
- Volunteers
- 60 people
- Sponsor
- Orion Corporation, Orion Pharma
Cardiac Function in Young Athletes
Study to Assess the Effect of OXYJUN on Ejection Fraction and Markers of Cardiovascular Injury
Young athletes are usually regarded as a special subgroup of healthy individuals with a unique lifestyle who are apparently invulnerable and often capable of extraordinary physical achievement.
- Trial name
- Enduoxy (NCT02207101)
- Testing
- E-OJ-01 (OXYJUN)
- Where
- India
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Vedic Lifesciences Pvt. Ltd.
Heart Failure
Quartet 1457Q Left Ventricular (LV) Lead Investigational Device Exemption (IDE) Study
The primary intent of this study is to assess the safety of the model 1457Q Quartet LV lead at 3 months in a patient population indicated for cardiac resynchronization therapy.
- Trial name
- NCT02548455
- Testing
- Quartet 1457Q LV Lead
- Where
- 30 sites in United States
- Volunteers
- 499 people
- Sponsor
- Abbott Medical Devices